Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with colon cancer (a specific type called adenocarcinoma) that has not yet been treated.
- People whose colon cancer is at a stage where surgery to remove it is possible (specifically classified as clinically T4N0 or Stage III).
- People whose tumor has been tested and shows a specific characteristic related to how the cancer's DNA repair system works — either "proficient mismatch repair" (MMRp), or "microsatellite stable" (MSS) or "microsatellite instability-low" (MSI-L) (confirm with trial site for testing details).
- People who are able to provide a fresh tissue sample taken from the tumor during a colonoscopy before or during the screening process.
- People who are willing to use adequate contraception during the trial, if applicable.
- People who are generally well enough to carry out light daily activities, as measured by a standard medical scale (ECOG performance status of 0 or 1).
- People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements.
Who may not be able to join:
- People whose cancer has spread to other parts of the body (distant metastasis).
- People who have already received any treatment for their colon cancer, including chemotherapy, immunotherapy, targeted therapy, radiation, or surgery.
- People whose tumor the treating doctor considers cannot be safely removed by surgery, or who have any other medical reason that makes surgery inadvisable.
- People who have previously had serious reactions to immunotherapy treatments, including severe immune-related side effects (Grade 3 or higher), serious nerve-related immune reactions of any severity, severe skin reactions such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, or DRESS syndrome, or immune-related heart muscle inflammation of any severity.
- People who have a history of, or currently have, a lung condition called interstitial lung disease or immune-related lung inflammation (pneumonitis).
- People who have a medical condition, ongoing treatment, or abnormal test results that the treating doctor believes could interfere with the trial or make participation unsafe.
- People who the treating doctor considers to be at serious medical risk due to an uncontrolled illness, a significant non-cancer disease, or an active infection requiring treatment.
- People who have taken part in another clinical trial and received an experimental treatment within the 4 weeks before starting this trial.
- People who are pregnant or breastfeeding.
- People who have had a severe allergic or anaphylactic reaction to similar types of antibody-based medicines, or who are known to have allergies to the specific drugs used in this trial (dostarlimab or the CAPEOX chemotherapy regimen).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 877-379-3718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Major pathological response (mPR) rate; Number of participants with adverse events (AEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to death or discontinuation of study intervention
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.